These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27855847)

  • 1. p15 Expression Differentiates Nevus from Melanoma.
    Taylor LA; O'Day C; Dentchev T; Hood K; Chu EY; Ridky TW; Seykora JT
    Am J Pathol; 2016 Dec; 186(12):3094-3099. PubMed ID: 27855847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma.
    McNeal AS; Liu K; Nakhate V; Natale CA; Duperret EK; Capell BC; Dentchev T; Berger SL; Herlyn M; Seykora JT; Ridky TW
    Cancer Discov; 2015 Oct; 5(10):1072-85. PubMed ID: 26183406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.
    Vredeveld LC; Possik PA; Smit MA; Meissl K; Michaloglou C; Horlings HM; Ajouaou A; Kortman PC; Dankort D; McMahon M; Mooi WJ; Peeper DS
    Genes Dev; 2012 May; 26(10):1055-69. PubMed ID: 22549727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.
    Goel VK; Ibrahim N; Jiang G; Singhal M; Fee S; Flotte T; Westmoreland S; Haluska FS; Hinds PW; Haluska FG
    Oncogene; 2009 Jun; 28(23):2289-98. PubMed ID: 19398955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of p15 in a spectrum of spitzoid melanocytic neoplasms.
    Ma SA; O'Day CP; Dentchev T; Takeshita J; Ridky TW; Seykora JT; Chu EY
    J Cutan Pathol; 2019 May; 46(5):310-316. PubMed ID: 30666677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF and NRAS mutations in melanoma and melanocytic nevi.
    Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
    Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
    Bahmad HF; Oh KS; Alexis J
    J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms.
    McBride JD; McAfee JL; Piliang M; Bergfeld WF; Fernandez AP; Ronen S; Billings SD; Ko JS
    J Cutan Pathol; 2022 Mar; 49(3):220-230. PubMed ID: 34476825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of activated Akt in benign nevi, Spitz nevi and melanomas.
    Kantrow SM; Boyd AS; Ellis DL; Nanney LB; Richmond A; Shyr Y; Robbins JB
    J Cutan Pathol; 2007 Aug; 34(8):593-6. PubMed ID: 17640227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry.
    Sparrow LE; Eldon MJ; English DR; Heenan PJ
    Am J Dermatopathol; 1998 Jun; 20(3):255-61. PubMed ID: 9650698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemistry of p16 in nevi of pregnancy and nevoid melanomas.
    Koh SS; Roehmholdt BF; Cassarino DS
    J Cutan Pathol; 2018 Dec; 45(12):891-896. PubMed ID: 30178478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.
    Damsky W; Micevic G; Meeth K; Muthusamy V; Curley DP; Santhanakrishnan M; Erdelyi I; Platt JT; Huang L; Theodosakis N; Zaidi MR; Tighe S; Davies MA; Dankort D; McMahon M; Merlino G; Bardeesy N; Bosenberg M
    Cancer Cell; 2015 Jan; 27(1):41-56. PubMed ID: 25584893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanocytic nevi and melanoma: unraveling a complex relationship.
    Damsky WE; Bosenberg M
    Oncogene; 2017 Oct; 36(42):5771-5792. PubMed ID: 28604751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving classification of melanocytic nevi: Association of BRAF V600E expression with distinct histomorphologic features.
    Kiuru M; Tartar DM; Qi L; Chen D; Yu L; Konia T; McPherson JD; Murphy WJ; Fung MA
    J Am Acad Dermatol; 2018 Aug; 79(2):221-229. PubMed ID: 29653212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of PRAME staining in identifying malignant transformation of melanocytic nevi.
    Lohman ME; Steen AJ; Grekin RC; North JP
    J Cutan Pathol; 2021 Jul; 48(7):856-862. PubMed ID: 33433032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective loss of wild-type p16(INK4a) expression in human nevi.
    Scurr LL; McKenzie HA; Becker TM; Irvine M; Lai K; Mann GJ; Scolyer RA; Kefford RF; Rizos H
    J Invest Dermatol; 2011 Nov; 131(11):2329-32. PubMed ID: 21734716
    [No Abstract]   [Full Text] [Related]  

  • 17. Cyclin D1 expression in melanocytic lesions of the skin.
    Ramirez JA; Guitart J; Rao MS; Diaz LK
    Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarker discovery analysis: Alterations in p14, p16, p53, and BAP1 expression in nevi, cutaneous melanoma, and metastatic melanoma.
    Sargen MR; Cloutier JM; Sarin KY; Rieger KE; Chu P; Swetter SM; Novoa RA
    Pigment Cell Melanoma Res; 2019 May; 32(3):474-478. PubMed ID: 30672662
    [No Abstract]   [Full Text] [Related]  

  • 19. Diagnostic utility of 5-hydroxymethylcytosine immunohistochemistry in melanocytic proliferations.
    Rodić N; Zampella J; Sharma R; Burns KH; Taube JM
    J Cutan Pathol; 2015 Nov; 42(11):807-14. PubMed ID: 26239102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamics of nevus development implicate cell cooperation in the growth arrest of transformed melanocytes.
    Ruiz-Vega R; Chen CF; Razzak E; Vasudeva P; Krasieva TB; Shiu J; Caldwell MG; Yan H; Lowengrub J; Ganesan AK; Lander AD
    Elife; 2020 Oct; 9():. PubMed ID: 33047672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.